BiotechTube

Lopinavir 400 mg/ritonavir 100 mg + Efavirenz

ApprovedTerminated
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Acquired Immune Deficiency Syndrome

Conditions

Acquired Immune Deficiency Syndrome

Trial Timeline

Oct 1, 2008 → Jan 1, 2011

NCT ID
NCT00775606

About Lopinavir 400 mg/ritonavir 100 mg + Efavirenz

Lopinavir 400 mg/ritonavir 100 mg + Efavirenz is a approved stage product being developed by Gilead Sciences for Acquired Immune Deficiency Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00775606. Target conditions include Acquired Immune Deficiency Syndrome.

What happened to similar drugs?

3 of 20 similar drugs in Acquired Immune Deficiency Syndrome were approved

Approved (3) Terminated (3) Active (14)
✅Zavicefta, Ceftazidime-AvibactamPfizerApproved
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
✅TelithromycinSanofiApproved
🔄IMI/REL FDC + PIP/TAZ FDC + LinezolidMerckPhase 3
🔄PI + RTV + FTC/TDF + StribildGilead SciencesPhase 3
🔄E/C/F/TDF + COBI + ATV + DRV + NRTIGilead SciencesPhase 3
🔄COBI + DRV + NRTIsGilead SciencesPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00775606ApprovedTerminated

Competing Products

20 competing products in Acquired Immune Deficiency Syndrome

See all competitors
ProductCompanyStageHype Score
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
35
epoetin alfaJohnson & JohnsonPhase 2
35
epoetin alfaJohnson & JohnsonPhase 2
35
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
42
Ticagrelor + PlaceboAstraZenecaPhase 2
27
IMI/REL FDC + PIP/TAZ FDC + LinezolidMerckPhase 3
40
Raltegravir + AtazanavirMerckPre-clinical
26
Emicizumab InjectionRochePhase 2
35
PI + RTV + FTC/TDF + StribildGilead SciencesPhase 3
40
E/C/F/TDF + COBI + ATV + DRV + NRTIGilead SciencesPhase 3
40
COBI + DRV + NRTIsGilead SciencesPhase 3
40
StribildGilead SciencesPhase 3
40
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOSGilead SciencesPhase 2/3
42
D/C/F/TAF + DRV + COBI + FTC/TDF + D/C/F/TAF Placebo + DRV Placebo + COBI Placebo + FTC/TDF PlaceboGilead SciencesPhase 2
35
E/C/F/TAF + E/C/F/TAF (Low Dose)Gilead SciencesPhase 2/3
38
E/C/F/TDF + ATV + RTV + FTC/TDF + E/C/F/TDF Placebo + ATV Placebo + RTV Placebo + FTC/TDF Placebo + E/C/F/TAFGilead SciencesPhase 3
40
NNRTI + FTC/TDF + StribildGilead SciencesPhase 3
40
E/C/F/TDF + E/C/F/TAF Placebo + E/C/F/TAF + E/C/F/TDF PlaceboGilead SciencesPhase 2
35
EVG + Background regimenGilead SciencesPhase 2/3
30
EVG/COBI/FTC/TDFGilead SciencesPhase 2/3
38